Novel biological therapeutic approaches to cutaneous lupus erythematosus

References

• Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981;4(4):471–475.
   PubMed Web of Science ®Google Scholar
• Hejazi EZ, Werth VP. Cutaneous lupus erythematosus: an update on pathogenesis, diagnosis and treatment. Am J Clin Dermatol. 2016;17:135–146.
   PubMed Web of Science ®Google Scholar
• Rothfield N, Rd S, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol. 2006;24(5):348–362.
   PubMed Web of Science ®Google Scholar
• Jarukitsopa S, Hoganson DD, Crowson CS, et al. Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States. Arthritis Care Res (Hoboken). 2015;67(6):817–828.
   PubMed Web of Science ®Google Scholar
• Gronhagen CM, Fored CM, Granath F, et al. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol. 2011;164(6):1335–1341.
   PubMed Web of Science ®Google Scholar
• Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039.
   PubMed Web of Science ®Google Scholar
• Presto JK, Werth VP. Cutaneous lupus erythematosus: current treatment options. Curr Treat Options Rheumatol. 2016;2(1):36–48.
   Google Scholar
• Presto JK, Hejazi EZ, Werth VP. Biological therapies in the treatment of cutaneous lupus erythematosus. Lupus. 2017 Feb;26(2):115–118.
   PubMed Web of Science ®Google Scholar
• Touma Z, Gladman DD, Ibanez D, et al. Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. J Rheumatol. 2011;38(2):275–284.
   PubMed Web of Science ®Google Scholar
• Klein R, Moghadam-Kia S, LoMonico J, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol. 2011;147:203–208.
   PubMedGoogle Scholar
• Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the sledai. a disease activity index for lupus patients. the committee on prognosis studies in SLE. Arthritis Rheum. 1992;35(6):630–640.
   PubMed Web of Science ®Google Scholar
• Touma Z, Urowitz MB, Gladma DD SLEDAI-2K. for a 30-day window. Lupus. 2010;19(1):49–51.
   PubMed Web of Science ®Google Scholar
• Symmons DP, Coppock JS, Bacon PA, et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus Members of the British Isles Lupus Assessment Group (BILAG). Q J Med. 1988;69(259):927–937.
   PubMedGoogle Scholar
• Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British isles lupus assessment group’s disease activity index for patients with systemic lupus erythematosus. Rheum (Oxford). 2005;44:902–906.
   PubMed Web of Science ®Google Scholar
• Krathen MS, Dunham J, Gaines E, et al. The cutaneous lupus erythematosus disease activity and severity index: expansion for rheumatology and dermatology. Arthritis Rheum. 2008;59(3):338–344.
   PubMedGoogle Scholar
• Yurasov S, Wardemann H, Hammersen J, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med. 2005;201(5):703–711.
   PubMed Web of Science ®Google Scholar
• Achtman JC, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Arthritis Res Ther. 2015;17:182.
   PubMed Web of Science ®Google Scholar
• Cobo-Ibanez T, Loza-Santamaria E, Pego-Reigosa JM, et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum. 2014;44(2):175–185.
   PubMed Web of Science ®Google Scholar
• Vital EM, Wittmann M, Edward S, et al. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheum. 2015;67(6):1586–1591.
   PubMed Web of Science ®Google Scholar
• Hofmann SC, Leandro MJ, Morris SD, et al. Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus–report of 17 cases and review of the literature. Lupus. 2013;22(9):932–939.
   PubMed Web of Science ®Google Scholar
• Alsanafi S, Kovarik C, Mermelstein AL, et al. Rituximab in the treatment of bullous systemic lupus erythematosus. J Clin Rheumatol. 2011;17(3):142–144.
   PubMed Web of Science ®Google Scholar
• Anyanwu CO, Ang CC, Werth VP. Oral mucosal involvement in bullous lupus. Arthritis Rheum. 2013;65(10):2622.
   PubMedGoogle Scholar
• Manzi S, Sánchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833–1838.
   PubMed Web of Science ®Google Scholar
• Hui-Yuen JS, Reddy A, Taylor J, et al. Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol. 2015;42(12):2288–2295.
   PubMed Web of Science ®Google Scholar
• Scheinberg M, de Melo FF, Bueno AN, et al. Belimumab for the treatment of corticosteroid-dependent systemic lupus erythematosus: from clinical trials to real-life experience after 1 year of use in 48 Brazilian patients. Clin Rheum. 2016;35(7):1719–1723.
   PubMed Web of Science ®Google Scholar
• Iaccarino L, Bettio S, Reggia R, et al. Response to belimumab in SLE patients with high disease activity: data from a multicentric clinical-practice based study cohort [abstract]. 2016 ACR/ARHP annual meeting abstract supplement. Arthritis Rheum. 2016;68:1–4550. Available from: http://acrabstracts.org/abstract/response-to-belimumab-in-sle-patients-with-high-disease-activity-data-from-a-multicentric-clinical-practice-based-study-cohort/.
   Web of Science ®Google Scholar
• Iaccarino L, Bettio S, Reggia R, et al. Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017;69:115–123.
   PubMed Web of Science ®Google Scholar
• Vashisht P, Borghoff K, O’Dell JR, et al. Belimumab for the treatment of recalcitrant cutaneous lupus. Lupus. 2017;26(8):857–864.
   PubMed Web of Science ®Google Scholar
• Gatto M, Iaccarino L, Zen M, et al. When to use belimumab in SLE. Expert Rev Clin Immunol. 2017;13:737–740.
   PubMed Web of Science ®Google Scholar
• Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358(9):929–939.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(10):3077–3087.
   PubMed Web of Science ®Google Scholar
• Danion F, Rosine N, Belkhir R, et al. Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease. Lupus. 2016;25(13):1440–1447.
   PubMed Web of Science ®Google Scholar
• Varada S, Gottlieb AB, Merola JF, et al. Treatment of coexistent psoriasis and lupus erythematosus. J Am Acad Dermatol. 2015;72(2):253–260.
   PubMed Web of Science ®Google Scholar
• Zimmer R, Scherbarth HR, Rillo OL, et al. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis. 2013;72(11):1830–1835.
   PubMed Web of Science ®Google Scholar
• Robinson ES, Werth VP. The role of cytokines in the pathogenesis of cutaneous lupus erythematosus. Cytokine. 2015;73(2):326–334.
   PubMed Web of Science ®Google Scholar
• Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheum. 2017;69:376–386.
   PubMed Web of Science ®Google Scholar
• Zheng B, Yu XQ, Greth W, et al. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients. Br J Clin Pharmacol. 2016;81(5):918–928.
   PubMed Web of Science ®Google Scholar
• Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75:1909–1916.
   PubMed Web of Science ®Google Scholar
• Werth VP, Fiorentino D, Sullivan BA, et al. Brief report: pharmacodynamics, safety, and clinical efficacy of amg 811, a human anti-interferon-gamma antibody, in patients with discoid lupus erythematosus. Arthritis Rheum. 2017;69(5):1028–1034.
   PubMed Web of Science ®Google Scholar
• Kitani A, Hara M, Hirose T, et al. Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. Clin Exp Immunol. 1992;88(1):75–83.
   PubMed Web of Science ®Google Scholar
• Urbanski A, Schwarz T, Neuner P, et al. Ultraviolet light induces increased circulating interleukin-6 in humans. J Invest Dermatol. 1990;94(6):808–811.
   PubMed Web of Science ®Google Scholar
• Stannard JN, Reed TJ, Myers E, et al. Lupus skin is primed for il-6 inflammatory responses through a keratinocyte-mediated autocrine type i interferon loop. J Invest Dermatol. 2017;137(1):115–122.
   PubMed Web of Science ®Google Scholar
• Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542–552.
   PubMed Web of Science ®Google Scholar
• Makol A, Gibson LE, Michet CJ. Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis. J Clin Rheumatol. 2012;18(2):92–95.
   PubMed Web of Science ®Google Scholar
• Szepietowski JC, Nilganuwong S, Wozniacka A, et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum. 2013;65(10):2661–2671.
   PubMed Web of Science ®Google Scholar
• De Souza A, Ali-Shaw T, Strober BE, et al. Successful treatment of subacute lupus erythematosus with ustekinumab. Arch Dermatol. 2011;147(8):896–898.
   PubMedGoogle Scholar
• Winchester D, Duffin KC, Hansen C. Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus. Lupus. 2012;21(9):1007–1010.
   PubMed Web of Science ®Google Scholar
• Dahl C, Johansen C, Kragballe K, et al. Ustekinumab in the treatment of refractory chronic cutaneous lupus erythematosus: a case report. Acta Derm Venereol. 2013;93(3):368–369.
   PubMed Web of Science ®Google Scholar
• Romero-Mate A, Garcia-Donoso C, Hernandez-Nunez A, et al. Successful treatment of recalcitrant discoid lupus erythematosus with ustekinumab. Dermatol Online J. 2017;23:1.
   Google Scholar
• van Vollenhoven R, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomized placebo-controlled study [abstract]. 2017 ACR/ARHP annual meeting abstract supplement. Arthritis & rheum (Hoboken, NJ). 2017;69:1–4426. Available from: http://acrabstracts.org/abstract/efficacy-and-safety-of-ustekinumab-an-interleukin-1223-inhibitor-in-patients-with-active-systemic-lupus-erythematosus-results-of-a-phase-2-randomized-placebo-controlled-study/.
   PubMedGoogle Scholar
• Reich A, Werth VP, Furukawa F, et al. Treatment of cutaneous lupus erythematosus: current practice variations. Lupus. 2016;25(9):964–972.
   PubMed Web of Science ®Google Scholar
• Muangchan C, van Vollenhoven RF, Bernatsky SR, et al. Treatment algorithms in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2015;67(9):1237–1245.
   PubMed Web of Science ®Google Scholar
• Medina-Rosas J, Al-Rayes H, Moustafa AT, et al. Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials. Expert Opin Biol Ther. 2016;16(10):1225–1238.
   PubMed Web of Science ®Google Scholar
• Stannard JN, Kahlenberg JM. Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus. Curr Opin Rheum. 2016;28(5):453–459.
   PubMed Web of Science ®Google Scholar
• Werth VP, Merola JF, Furie R, et al. 1081 BIIB059, a monoclonal antibody targeting BDCA2, decreases Type I Interferon-related genes transcriptional activity in subjects with systemic lupus erythematosus (SLE) and active cutaneous LE (CLE). J Investigative Dermatol. 2018;138(5):S183.
   Web of Science ®Google Scholar